Treatment of Thromboembolism of Lower Limb Arteries in Antiphospholipid Syndrome

This protocol covers the management of thromboembolism of lower limb arteries presenting as embolism to lower extremity peripheral arteries in a patient with antiphospholipid syndrome.

Clinical Scenario

Embolism to lower extremity peripheral arteries in the setting of antiphospholipid syndrome — a condition associated with a markedly elevated risk of recurrent thromboembolism that shapes the choice and intensity of anticoagulation.

Treatment Approach

Full-dose anticoagulation with warfarin (a vitamin K antagonist) is the indicated approach in this scenario. Therapy is titrated to reach and maintain a specific therapeutic INR target.

The complete protocol — including titration strategy, monitoring schedule, and management of out-of-range values — is available in the full structured regimen below.

Therapeutic Goal

The primary objective is to achieve and sustain a therapeutic INR within the evidence-based target range defined for this population.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3389/fcvm.2021.773214

Warfarin can of course still be used as an alternative for prevention of systemic thromboembolic events in patients with AF or other sources of embolism to peripheral arteries, however, and is superior to dabigatran in patients with mechanical heart valves and to rivaroxaban in those with antiphospholipid syndrome.

The therapeutic target is an international normalized ratio (INR) of 2.0-3.0.

View source ↗